Azenta, Inc. (AZTA)

Azenta's stock price has fluctuated, decreasing by 3.07% over the last 12 months with a year-to-date return of -22.10% as of April 25, 2026, but increasing by 21.59% in the preceding month. A significant event occurred on May 5, 2026, when Azenta reported disappointing second-quarter fiscal 2026 results, including a $149 million non-cash goodwill impairment charge, leading to a share price decline of approximately 25%. Other events include the acquisition of UK Biocentre Limited on March 4, 2026, and a strategic partnership with Frontier Space on February 9, 2026.

There appears to be some seasonality in the demand for Azenta's products and services, particularly within its Multiomics segment in North America. Management noted that the "month three spike seasonality just did not materialize" for Multiomics in North America. The company has also observed "ongoing North America demand weakness in Multiomics and capital-intensive products" and "prolonged softness" in capital equipment demand within its Sample Management Solutions segment.

Azenta, Inc. is a global provider of life sciences solutions, operating in the Healthcare sector, specifically in the Medical Instruments & Supplies and Medical Devices & Instruments industries. The company's business is divided into Sample Management Solutions, offering cold-chain products and services, and Multiomics, focusing on genomic services through gene sequencing, synthesis, and editing.

Azenta, Inc. has a global presence with facilities across North America, Europe, and Asia. In North America, it has locations in Waltham, Indianapolis, and La Jolla, with its headquarters in Burlington, Massachusetts. European operations include a biorepository in Griesheim, Germany, and an expanded presence in the UK following the acquisition of UK Biocentre Limited.

Azenta's brand reputation has been negatively impacted by disappointing Q2 fiscal 2026 results, including a significant goodwill impairment charge and lowered full-year guidance. Management acknowledged "execution gaps" and a "more cautious demand environment." An investigation into potential securities fraud was announced following the Q2 earnings report, which could further affect the company's reputation.

Azenta, Inc.'s ownership is predominantly held by institutional investors, accounting for well over 90% of outstanding shares. Major institutional shareholders include BlackRock, Inc., Politan Capital Management LP, and Vanguard Group Inc, among others.